The Psychiatric and Cognitive Phenotypes in Velocardiofacial Syndrome (VCFS)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00768820 |
Recruitment Status :
Recruiting
First Posted : October 8, 2008
Last Update Posted : March 9, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Velocardiofacial Syndrome Williams Syndrome Fragile X Syndrome | Drug: methylphenidate, fluoxetin, risperidone | Phase 4 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 400 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Diagnostic |
Official Title: | The Psychiatric and Cognitive Phenotypes in Velocardiofacial Syndrome (VCFS), Williams Syndrome (WS)and Fragile X Syndrome Characterization, Treatment and Examining the Connection to Developmental and Molecular Factors |
Study Start Date : | May 2001 |
Estimated Primary Completion Date : | December 2022 |
Estimated Study Completion Date : | December 2022 |

Arm | Intervention/treatment |
---|---|
Experimental: 1 |
Drug: methylphenidate, fluoxetin, risperidone
first cognitive evaluation without methylphenidate,second cognitive evaluation with methylphenidate |
- Measure that are used: psychological measures, molecular tests, responsiveness to medical treatments [ Time Frame: 2 years ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | Child, Adult, Older Adult |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- chromosomal deletion proven by FISH examination
Exclusion Criteria:

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00768820
Contact: Doron Gothelf, MD | 972-03-5302663 | gothelf@post.tau.ac.il |
Israel | |
Schneider Children's Mediac Center of Israel | Recruiting |
Petach-Tikva, Israel, 49202 | |
Contact: Doron Gothelf, MD 972-03-5302663 |
Responsible Party: | Prof. Doron Gothelf, Principal Investigator, The Chaim Sheba Medical Center |
ClinicalTrials.gov Identifier: | NCT00768820 |
Other Study ID Numbers: |
SCMCI082455CTIL |
First Posted: | October 8, 2008 Key Record Dates |
Last Update Posted: | March 9, 2022 |
Last Verified: | March 2022 |
Velocardiofacial syndrome Williams syndrome fragile X syndrome cognitive phenotype psychiatric phenotype |
DiGeorge Syndrome Fragile X Syndrome Williams Syndrome Syndrome Disease Pathologic Processes Mental Retardation, X-Linked Intellectual Disability Neurobehavioral Manifestations Neurologic Manifestations Nervous System Diseases Sex Chromosome Disorders Chromosome Disorders Congenital Abnormalities Genetic Diseases, Inborn |
Genetic Diseases, X-Linked Heredodegenerative Disorders, Nervous System Aortic Stenosis, Supravalvular Aortic Valve Stenosis Aortic Valve Disease Heart Valve Diseases Heart Diseases Cardiovascular Diseases 22q11 Deletion Syndrome Craniofacial Abnormalities Musculoskeletal Abnormalities Musculoskeletal Diseases Heart Defects, Congenital Cardiovascular Abnormalities Lymphatic Abnormalities |